Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

Similar articles for PubMed (Select 15886158)

1.

Overcoming economic barriers to the optimal use of vaccines.

Lieu TA, McGuire TG, Hinman AR.

Health Aff (Millwood). 2005 May-Jun;24(3):666-79.

2.

What are affordable vaccines?

Rappuoli R.

Lancet. 2015 Mar 28;385(9974):1177-8. doi: 10.1016/S0140-6736(15)60627-4. No abstract available.

PMID:
25845785
3.

Is tiered pricing the way for vaccines?

Balasegaram M.

Lancet. 2014 Sep 6;384(9946):852. doi: 10.1016/S0140-6736(14)61483-5. No abstract available.

PMID:
25209481
4.

Global vaccine supply. The increasing role of manufacturers from middle income countries.

Francis DP, Du YP, Precioso AR.

Vaccine. 2014 Sep 15;32(41):5259-65. doi: 10.1016/j.vaccine.2014.07.069. Epub 2014 Aug 8.

PMID:
25110294
5.

Vaccine development and developing countries.

[No authors listed]

Lancet. 2014 Jun 21;383(9935):2099. doi: 10.1016/S0140-6736(14)61012-6. No abstract available.

PMID:
24953461
6.

Better vaccines for healthier life. Part II. Conference report of the DCVMN International 14th Annual General Meeting Hanoi, Vietnam.

Pagliusi S, Tippoo P, Sivaramakrishnan V, Nguyen T; DCVMN Executive Committee.

Vaccine. 2014 Nov 12;32(48):6330-5. doi: 10.1016/j.vaccine.2014.05.076. Epub 2014 Jun 9.

7.

Economics and financing of vaccines for diarrheal diseases.

Bartsch SM, Lee BY.

Hum Vaccin Immunother. 2014;10(6):1568-81. doi: 10.4161/hv.28885. Epub 2014 Apr 22. Review.

PMID:
24755623
8.
9.

Not All Vaccines are Cost-beneficial in Developing Countries.

Garg A, Golwala Z.

J Glob Infect Dis. 2013 Apr;5(2):89-90. doi: 10.4103/0974-777X.112291. No abstract available.

10.

Policy trap and optimal subsidization policy under limited supply of vaccines.

Yi M, Marathe A.

PLoS One. 2013 Jul 1;8(7):e67249. doi: 10.1371/journal.pone.0067249. Print 2013.

12.

Vaccine pricing: how can we get it right?

Jacobson SH.

Expert Rev Vaccines. 2012 Oct;11(10):1163-5. doi: 10.1586/erv.12.95. No abstract available.

PMID:
23176647
13.

Desirable attributes of vaccines for deployment in low-resource settings.

Chen D, Zehrung D.

J Pharm Sci. 2013 Jan;102(1):29-33. doi: 10.1002/jps.23352. Epub 2012 Nov 7. Review.

PMID:
23136115
14.

Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil.

Ho PL, Miyaji EN, Oliveira ML, Dias Wde O, Kubrusly FS, Tanizaki MM, Martins EA, Raw I.

PLoS Negl Trop Dis. 2011 Nov;5(11):e1300. doi: 10.1371/journal.pntd.0001300. Epub 2011 Nov 29. Review. No abstract available.

15.

Transparent pricing of vaccines would help poor as well as rich countries.

Hecht R, Kaddar M, Schmitt S.

BMJ. 2011 Nov 23;343:d7414. doi: 10.1136/bmj.d7414. No abstract available.

PMID:
22113835
16.

An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines.

Saxenian H, Cornejo S, Thorien K, Hecht R, Schwalbe N.

Health Aff (Millwood). 2011 Jun;30(6):1122-33. doi: 10.1377/hlthaff.2011.0332.

17.

Vaccines as a global imperative--a business perspective.

St├ęphenne J.

Health Aff (Millwood). 2011 Jun;30(6):1042-8. doi: 10.1377/hlthaff.2011.0338.

18.

During the 'decade of vaccines,' the lives of 6.4 million children valued at $231 billion could be saved.

Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, Walker DG, Levine OS.

Health Aff (Millwood). 2011 Jun;30(6):1010-20. doi: 10.1377/hlthaff.2011.0381.

19.

The optimal number of routine vaccines to order at health clinics in low or middle income countries.

Rajgopal J, Connor DL, Assi TM, Norman BA, Chen SI, Bailey RR, Long AR, Wateska AR, Bacon KM, Brown ST, Burke DS, Lee BY.

Vaccine. 2011 Jul 26;29(33):5512-8. doi: 10.1016/j.vaccine.2011.05.044. Epub 2011 May 30.

20.

Vaccine progress reveals resource gaps in developing countries.

Burki TK.

Lancet Infect Dis. 2011 Mar;11(3):165-6. No abstract available.

PMID:
21491698
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk